Key result
Higher serum apolipoprotein A1 was associated with a lower prevalence of CKD and higher eGFR in two large multiethnic population samples.
Why the study?
Are circulating levels of apolipoprotein A1, apolipoprotein B, and their ratio associated with kidney function and chronic kidney disease in the general population?
Observational (n=17,315)
Yes
Are circulating levels of apolipoprotein A1, apolipoprotein B, and their ratio associated with kidney function and chronic kidney disease in the general population?
Higher serum apolipoprotein A1 is associated with a lower prevalence of CKD and higher eGFR, whereas apolipoprotein B shows no consistent associations.
Answers are grounded in this paper and cite their sources.
Higher ApoA1 may support kidney health in observational data; leaves open causality and should not yet change practice.
BACKGROUND: Circulating lipoproteins and their protein constituents, apolipoproteins, are risk factors for chronic kidney disease (CKD). The associations between apolipoprotein A1, apolipoprotein B and their ratio with glomerular filtration rate estimated from the new CKD Epidemiology Collaboration (CKD-EPI) equation (eGFR) are not well studied in the general population. METHODS: Associations between apolipoprotein A1, B and their ratio with the outcomes of eGFR, CKD (eGFR<60 mL/min/1.73 m2) and albuminuria were examined in the Atherosclerosis Risk in Communities study (ARIC, n=10,292, 1996-98) and the Third National Health and Nutrition Examination Survey (NHANES III, n=7023, 1988-91). Cross-sectional multivariable-adjusted analyses were performed using linear and logistic regression. Prospective analyses related baseline apolipoprotein levels to subsequent CKD incidence over 10 years using the ARIC Carotid MRI follow-up cohort (n=1659). RESULTS: Higher apolipoprotein A1 quartiles were associated with a lower prevalence of CKD [Q4 versus Q1: odds ratio (OR) 0.73, P-trend=0.02 in ARIC; Q4 versus Q1: OR 0.53, P-trend<0.01 in NHANES III] as well as with higher eGFR (P-trend<0.01 in ARIC and NHANES III). No consistent significant associations were found for apolipoprotein B in either study. The apolipoprotein B/A1 ratio was significantly associated with eGFR across quartiles in both studies (P-trend<0.01) and with CKD in ARIC (Q4 versus Q1: OR 1.23, P-trend=0.01). Prospectively, there were trends for the association of apolipoproteins with incident CKD [Q4 versus Q1: incidence rate ratio (IRR)=0.68 for apolipoprotein A1, P-trend=0.1; Q4 versus Q1: IRR=1.35 for apolipoprotein B, P-trend=0.2]. Associations were not systematically stronger when comparing traditional lipids (total cholesterol, low-density lipoprotein or high-density lipoprotein) to apolipoproteins. CONCLUSIONS: Higher serum apolipoprotein A1 was associated with lower prevalence of CKD and higher eGFR estimated by the CKD-EPI equation in two large multiethnic population-based samples. While apolipoprotein B showed no consistent associations, a higher apolipoprotein B/A1 ratio was significantly associated with lower eGFR in both studies. The direction and magnitude of the longitudinal associations between apolipoproteins and CKD incidence were overall similar to those observed cross-sectionally. No consistent differences became apparent between traditional lipids and apolipoproteins.
No takes yet. Share an insight, caveat, or question.
Goek et al. (2012) conducted an observational in Chronic kidney disease (n=17,315). Apolipoprotein A1 and B vs. Lower quartiles (Q1) was evaluated on CKD (eGFR<60 mL/min/1.73 m2) (OR 0.73, p=0.02). Higher serum apolipoprotein A1 was associated with a lower prevalence of CKD and higher eGFR in two large multiethnic population samples.
Synapse has enriched 10 related papers. Consider them for comparative context: